A strength of Evolving treatment patterns and outcomes in older AML: changing everything to change nothing? is documenting the suspected increasing use of non-intensive induction therapy in persons age ≥60 years from 1% 1999 to 2006 to 23% from 2007, when azacytidine and decitabine became widely available in Spain, to 2013 . Use of intensive chemotherapy decreased from 58% to 32%. Supportive care and clinical trial percentages remained constant (27–28% and 0–2%, respectively). Despite the more common use of non-intensive induction, survival was unchanged, with a median of 4.3 months, 1-year survival of 29% and 5-year survival of 7%. This explains the subtitle changing everything to change nothing?
As the authors acknowledge, the data derive from a cooperative group registry, rather than a population-based system and thereby include only hospitalized persons. The typescript might have benefitted from multivariable analyses comparing survival in the two intervals after accounting for differences in potentially confounding covariates such as age distribution or cytogenetics or, similarly, comparing less versus more intense induction.
Many may see limitation of analyses to 1999–2013 as problematic. Change nothing seems inappropriate given recent regulatory approvals of venetoclax with low dose cytarabine (LDAC), azacytidine or decitabine, and glasdegib with LDAC, for older persons with newly diagnosed AML. Randomized clinical trials involving these drugs report statistically significant improvements and clinically meaningful benefits . Clearly, these drugs are advances. They lengthen survival, the outcome people often care most about [3,4,5]. They prolong event-free survival (EFS), perhaps a better measure of drug efficacy . They increase response rates, although the contributions to survival or EFS of responses less than complete remission is largely unknown . They increase rates of transfusion independence of indeterminant duration. Venetoclax + LDAC improve quality of life measures versus LDAC , but these measures were the same with venetoclax + azacytidine versus azacytidine .
This commentary discusses issues these new drugs present: (1) stereotyped criteria for statistical significance and power which ignore the specifics of AML, (2) conflation between statistical significance and medical benefit, and (3 uncritical adoption of the phrase meaningful clinical benefit.
The venetoclax [3, 4] and glasdegib trials  were statistical successes with p values < 0.05 favoring the investigational drug. A p value < 0.05 is so entrenched in the clinical trial mindset that when the pre-specified comparison between LDAC ± venetoclax produced p = 0.11, further analyses, including one which resulted in p < 0.05 after an additional 6 months of follow-up, were done, despite the dubious statistical validity of this practice [8, 9]. A skeptic might wonder whether these analyses would have been done had the initial p value been < 0.05 or if another analysis is planned after a further 6 months of follow-up to see if the p value remains < 0.05. But my point is the almost invariant use of a false positive rate of at most 5% (p = 0.05) and of a false negative rate at most 20% (power = 80%) regardless of the disease in question. More concern should perhaps attach to a false positive in a trial of a new drug for hypertension, where there are already effective therapies, compared with a false positive in AML where we lack effective therapies for older persons, such that less is lost in replacing the standard of care with an ineffective treatment. Perhaps the p value of interest in hypertension should be <0.01 and in AML < 0.10. The same reasoning suggests acceptance of a lower false negative rate in AML.
Granted statistical significance, the medical benefit of the new drugs is less clear. The absolute gain in median survival was largest in the trial adding venetoclax to azacytidine with medians of 14.7 versus 9.6 months; this trial also reported the longest median survival following addition of the investigational drug. The median 5-month survival gain with venetoclax added to azacytidine might let a 75-year old see a grandchild married. But other 75-year-old persons might be less satisfied with a 14.7-month median survival, which translates to an 85–90% reduction in their average life expectancy. https://www.ssa.gov/oact/population/longevity.html.
Things would be easier were we able to predict Mr. X would live much longer than the 14.7-month median and Ms. Y much less. But we typically overestimate our prognostic ability .
Given the above I believe we should refrain from use of meaningful clinical benefit. In instances where absolute survival or EFS benefits are small, the term’s meaning is often in the eyes of the beholder. Beholders such as persons committed to executing a clinical trial of a new drug cannot be expected to be fully disinterested. Livingston provides an instructive example of how the relevance of such differences is a matter of perspective . Consideration might be given to polling patients to assess what they consider meaningful clinical benefit.
I agree venetoclax + azacytidine is the new standard of comparison for persons unfit for intensive therapy. Identification of such persons is often subjective . Furthermore, one properly informed person  might prefer venetoclax + azacytidine whilst another might prefer enrollment into a clinical trial. Examples include replacing parenteral with oral azacytidine or adding various drugs to venetoclax + azacytidine. Hopefully the publicity surrounding the recently approved drugs will not blind people to their relatively modest gains, lead physicians and patients with AML to complacency, and decrease accrual into new clinical trials. Although the advances are most welcome we are a very long way from curing older persons with AML.
Martinez-Cuadrón D, Serrano L, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón J, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. e-published 19 October 2020
Wei AH, DiNardo CD. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135:85–96.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MV, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax + LDAC for newly-diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized, placebo-controlled trial. Blood. 2020;135:2137–45.
Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–89.
Estey E, Othus M, Lee SJ, Appelbaum FR, Gale RP. New drug approvals in acute myeloid leuekmia: what’s the best endpoint? Leukemia. 2016;30:521–5.
Estey E, Karp JP, Othus M, Emadi A, Gale RP. Recent drug approvals for newly-diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020;34:671–81.
Amrhein V, Greenland S, McShane B. Retire statistical significance. Nature. 2019;367:305–7.
Gale RP, Hochhaus A, Zhang MJ. What is the (p-) value of the P-value? Leukemia. 2016;30:1965–7.
Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukaemia? Leukemia. 2017;31:1255–8.
Livingston E. Success of antibiotic therapy vs laparoscopic appendectomy for uncomplicated appendicitis in children; a matter of perspective. JAMA. 2020;324:594.
Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, et al. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. Haematologica. 2018;103:2040–8.
Schiffer CA. An important gap in informed consent documents for oncology clinical trials: lack of quantitative data about expected treatment outcomes. JAMA Oncol. 2019;5:1399–400.
Conflict of interest
The author declares that he has no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Estey, E. New treatments for acute myeloid leukemia: how much has changed?. Leukemia 35, 45–46 (2021). https://doi.org/10.1038/s41375-020-01084-2